𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis

✍ Scribed by Marek Wroński; Gilbert Lederman


Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
55 KB
Volume
80
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


The addition of cisplatin to cyclophosph
✍ Thierry Urban; Claude Chastang; François-Xavier Lebas; Jean-Paul Duhamel; Guy Ad 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## BACKGROUND. To assess whether the addition of cisplatin (100 mg/m 2 administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m 2 on Day 1], doxorubicin [45 mg/m 2 on Day 1], and etoposide [150 mg/m 2 on Days 1 and 2] combination is useful in the treatment of patients with small cel

Assessment of antibodies to double-stran
✍ P. J. Charles; R. J. T. Smeenk; J. De Jong; M. Feldmann; R. N. Maini 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 2 views

Objective. To compare the incidence of antidouble-stranded DNA (anti-dsDNA) antibodies in rheumatoid arthritis (RA) patients receiving either single or multiple doses of a chimeric anti-tumor necrosis factor ␣ (anti-TNF␣) antibody or placebo infusions, with or without methotrexate, in open-label, ra

Low-dose prednisolone in addition to the
✍ Björn Svensson; Annelies Boonen; Kristina Albertsson; Désirée van der Heijde; Ca 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB 👁 1 views

## Abstract ## Objective To assess the efficacy of low‐dose prednisolone on joint damage and disease activity in patients with early rheumatoid arthritis (RA). ## Methods At the start of their initial treatment with a disease‐modifying antirheumatic drug (DMARD), patients with early (duration ≤1

A multicentre, randomized, double-blind,
✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre